Research progress of IL33/ST2 in acute coronary syndrome

doi:10.12092/j.issn.1009-2501.2018.09.018

Abstract

Abstract:

The interleukin-33 (IL-33), which is a new member of the Interleukin-1(IL-1) immunoglobulin family, binds to the target cell membrane growth-stimulating expression gene 2 (ST2) to form a trans membrane complex. The IL-33/ST2 signaling pathway is involved in many inflammatory and immune diseases with the activation of Th2. In recent years, many studies have reported that IL-33/ST2 signaling pathway also plays an important role in cardio- and cerebro-vascular diseases such as coronary heart disease. Acute coronary syndrome (ACS) is a serious type of coronary heart disease based on the process of plaque rupture and erosion following the inflammatory lesions of coronary artery. This article aims to provide a new target and idea for the treatment of acute coronary syndrome by reviewing the progress of the studies of IL-33/ST2 signaling in acute coronary syndrome.

Key words: interleukin-33, growth-stimulating expression gene 2, acute coronary syndrome

CLC Number:

R541.4

ZHANG Qian, FU Hong, CHEN Jinjin, ZHU Yubing. Research progress of IL33/ST2 in acute coronary syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1075-1080.

References

［1］刘善辉,张世超,吉尚戎.IL-33活性调节及在疾病中的调控作用［J］.生物学杂志,2017,34(3): 78-81.
［2］刘巍.非ST段抬高急性冠脉综合征的诊断及治疗2014年AHA/ACC NSTE-ACS指南解读［J］.中西医结合心血管病电子杂志,2015,(3):1-3.
［3］孙爱梅,陈还珍.IL-33/ST2信号通路在心血管疾病中的研究进展［J］.中华临床医师杂志,2016, 10(10):1484-1487.
［4］黄静,陈还珍,韩瑾,等.ST2在心血管疾病方面研究新进展［J］.中国医学创新,2016,13 (25): 87-89.
［5］肖伟,罗艺.小鼠局灶性脑缺血再灌注后IL-33及其受体的时程表达［J］.中风与神经疾病, 2017,34(3):202-207.
［6］McLaren JE,Michael DR,Salter RC,et al.IL-33 reduces macrophage foam cell formation.［J］.The Journal of Immunology,2010,185(2):1222-1229.
［7］徐成斌.急性冠脉综合征的病理与病理生理学［J］.中国医刊,2001,36(11):6-8.
［8］Lingel A,Weiss TM,Niebuhr M,et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes［J］. Structure,2009,7(10): 1398-1410.
［9］Kunes P,Mandak J,Holubcova,et al. Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot［J］?Perfusion,2015,30(5):356-374.
［10］Dieplinger B,Mueller T.Soluble ST2 in heart failure［J］.Int J Clin Chem,2015,443:57-70.
［11］De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: Role in health and disease ［J］. Cytokine Growth Factor Rev, 2010,6(26):615-623.
［12］Guzel S,Serin O,Guzel EC,et al.Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor ［corrected］ of matrix metalloproteinase-1 in myocardial infarction［J］.Korean J Intern Med,2013,2(28):165-173.
［13］Al Shahi H,Shimada K,Miyauchi K,et al. Elevated circulating levels of inflammatory markers in patients with acute coronary syndrome［J］.Int J Vasc Med,2015,2015:805375.
［14］Pfetsch V,Sanin V,Jaensch A.Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the KAROLA study［J］.Cardiovasc Drugs Ther,2017,31(2):167-177.
［15］施冰,吴龙梅,李俊峡,等.可溶性ST2检测在急性冠状动脉综合征的临床应用［J］.岭南心血管病杂志,2016,22(5):509-512.
［16］Eggers KM,Armstrong PW,Califf RM,et al.ST2 and mortality in non-ST-segment elevation acute coronary syndrome［J］.Am Heart J,2010,159(5):788-794.
［17］Kohli P,Bonaca MP,Kakkar R,et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial［J］.Clin Chem, 2012,58(1):257-266.
［18］Chen B,Geng J,Gao SX,et al Eplerenone modulates Interleukin-33/sST2 Signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction［J］.J Interferon Cytokine Res,2018,38(3):137-144.
［19］Sabatine MS,Morrow DA,Higgins LJ,et al.Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction［J］.Circulation,2008,117(15):1936-1944.
［20］Yu J,Oh PC,Kim M,et al.Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP［J］.PloS one,2017,12(8):e0182829.
［21］Weir RA,Miller AM,Murphy G.Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction［J］.J Am Coll Cardiol, 2010, 55 (3):243-250.
［22］Shimpo M,Morrow DA,Weinberg EO,et al.Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction ［J］.Circulation,2004,109(18):2186-2190.
［23］兰志明,刘鹏.ST2与冠心病的研究进展［J］.中国医药科学,2017,7(4):38-40.
［24］Lax A,Sanchez-Mas J,Asensio-Lopez MC,et al.Mineralocorticoid receptor antagonists modulate galectin-3 and Interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial Infarction［J］.JACC Heart Fail,2015,3(1):50-58.
［25］Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress［J］.Biochem Pharmacol, 2017, 138:73-80.
［26］Sánchez-Más J,Lax A,Asensio-López Mdel C,et al.Modulation of IL-33/ST2 system in post infarction heart failure: correlation with cardiac remodelling markers［J］.Eur J Clin Invest, 2014, 44 (7):643-651.
［27］Lupón J,Gaggin HK,de Antonio M,et al.Biomarker-assist score for reverse remodeling prediction in heart failure:The ST2-R2 score［J］.Int J Cardiol,2015,184:337-343.
［28］Moore SA,Januzzi JL Jr.Found in translation soluble ST2 and heart disease［J］.J Am Coll Cardiol, 2010,55(3):251-253.
［29］李惠,肖普马曹.ST2基因多态性与冠状动脉疾病的相关性［J］.中国老年学杂志, 2017, 37(8): 1917-1919.
［30］Tu X,Nie S,Liao Y,et al.The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population［J］.Am J Hum Genet,2013,93(4):652-660.
［31］Tsapaki A, Zaravinos A, Apostolakis S,et al.Genetic variability of the distal promoter of the ST2 gene is associated with coronary artery disease［J］.J Thromb Thrombolysis,2010,30 (3):365-371.
［32］Wu F,He M,Wen Q,et al.Associations between Variants in IL-33/ST2 Signaling Pathway Genes and Coronary Heart Disease Risk. Int J Mol Sci［J］.Int J Mol Sci,2014,15(12): 23227-23239.

[1]	PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu. Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
[2]	DENG Yifan, HE Shenghu, WANG Daxin, DAI Chengye, XU Xiaoting, ZHANG Jing. Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1048-1052.
[3]	ZHANG Xia, KE Yong-sheng. Clinical research of new type P2Y12 Receptor inhibitor ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
[4]	ZHOU Bi-rong, CHEN Yue-feng, ZHOU Na, YANG Jing. Changes of hs-CRP, CatS level in acute coronary syndrome patients serum and clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1036-1039.
[5]	ZHANG Yin-zhuang, CHEN Bi-lian. Research progress on the platelet P₂Y₁₂ receptor antagonists [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 824-830.
[6]	JIA Liang-liang, KE Yong-sheng. Anticoagulation strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 469-475.
[7]	JIA Liang-Liang, KE Yong-sheng. Antiplatelet strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1074-1080.
[8]	QIAN Jian, XU Jian. Effects of simvastatin combining clopidogrel on high-sensitivity C-reactive protein and blood lipids in patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 206-209.
[9]	KE Yong-sheng. Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 361-367.
[10]	CHEN Bi-lian, XIE Qin-zhi, LI Qing. Clinical observation of clopidogrel resistance and clinical outcomes on patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 328-332.
[11]	WU Xu-bin, QIAN Zong-jie, WU Guang-wei, LIN Ying-zhong, HU Chang-xin. Effects of rosiglitazone on the synthesis of tumor necrosis factor-alpha and tissue factor in peripheral blood monouclear cells from patients with acute coronary syndrome without diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 180-185.
[12]	WU Xu-bin, TANG Sheng-xin, WU Guang-wei, LIN Ying-zhong, HU Chang-xin. Effects of atorvastain on tissue factor and tumor necrosis factor-alpha synthesis in peripheral blood monocytes from patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 98-102.
[13]	YAN Yu-xiang, LI Jing, GUO mei, LIU Deng-xian. Efficiency and safety of Fraxiparin for patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(11): 1317-1320.
[14]	LIU Yan, CHEN Shao-liang, LIU Zhi-zhong. Significance of coronary collaterals in patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 681-683.